Articles related to LUNG CANCER

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

A look into the FDA’s rigorous 2023 drug approval process, including a record number of new medicines and notable rejections. Understanding these trends is essential for anticipating future treatment landscapes.

In the intricate realm of chest X-ray interpretation, AI shines in detecting diseases but falls short in discerning their absence, especially in complex cases. Lead author Dr. Louis Plesner cautions against relying solely on AI, emphasizing the indispensable role of human radiologists.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.

The study underscores the potential of osimertinib-chemotherapy combination as a first-line treatment in EGFR-mutated advanced NSCLC, demonstrating a significant improvement in progression-free survival and response rate compared to osimertinib monotherapy.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.